Tag:
Biogen Idec
Latest Headlines
Latest Headlines
Biogen's impressive Tecfidera launch hits reimbursement, supply snags
Biogen Idec's new multiple sclerosis pill Tecfidera is selling so well that it's expected to break the blockbuster barrier by next year. But the launch has hit a few bumps.
Royalty's $8B offer wilts after Elan prevails in blocking bid
Royalty Pharma signed the death certificate on its $8 billion bid for biotech Elan, withdrawing its appeal of a decision from an Irish panel that blocked its ability to alter the terms of its latest hostile takeover attempt.
Biogen Idec taps brakes on EU launch of oral MS drug Tecfidera
Biogen Idec has taken steps to provide a strong and durable fortress around intellectual property for its potential blockbuster Tecfidera in the European Union, but the effort is going to require additional time.
Does pharma spend more on marketing than R&D? A numbers check
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
Biotech Receptos claims $73M IPO prize to fuel oral MS contender
San Diego-based biotech Receptos has priced an initial public offering of 5.2 million shares at $14, raising $72.8 million as the company closes in on late-stage development of its lead candidate for multiple sclerosis.
Biogen's HQ plans change, thanks to early Tecfidera success
What happens when a new drug comes charging out of the launch gate? For Biogen Idec, it means a rethink of its real estate plans.
Fast-growing Biogen Idec bursts the seams at new Cambridge HQ
When George Scangos took the helm at Biogen Idec, he left little doubt that he couldn't much stand the company's gleaming new headquarters in Weston, MA, the brainchild of ex-CEO Jim Mullen. R&D in Cambridge was where it was at, and that's where he spent the bulk of his time.
Amid $2B in cost-cutting, Teva sales suffer from generic erosion
Teva Pharmaceutical Industries may be a generics behemoth, but its earnings this quarter bore a more-than-casual resemblance to Big Pharma's.
Martin Leach's 16-year interview for the job of Big Data boss at Biogen Idec
Martin Leach has spent the past several months building a new data sciences group at Biogen Idec, where his team of informatics and tech pros has undertaken the sizable task of enabling scientists and others at the biotech powerhouse to make use of Big Data.
UPDATED: Biogen CEO Scangos scores 19% pay hike during stellar 2012
Biogen Idec CEO George Scangos took home one of the largest pay packages in the biotech industry in 2012--a total of $13.45 million in 2012, a 19% jump in pay from his $11.33 million pay package the previous year, the Weston, MA-based company reported Monday in a proxy statement.
